Professional Documents
Culture Documents
Introduction
Intracavitary Brachytherapy
Fletcher-Suit applicator
Interstitial Brachytherapy
Radium Needles
Prostate Brachytherapy
Prostate Brachytherapy
Iodine 125
t = 60 days Gamma emitter
Energy 35 kV
Prostate Brachytherapy
Prostate Brachytherapy
Adverse effects Urinary symptoms common
Dysuria, frequency, urgency, nocturia
Acute urinary retention 1-14% Urinary incontinence 5- 6% Proctitis 1-3% But Sexual potency preserved 86 -96%
At 2 3 years
Prostate Brachytherapy
Results:
Gleason 2-4 Gleason 5-6 PSA < 4 PSA 4 -10
T1c T2a
Prostate Brachytherapy
Patient Selection
PSA < 10 Gleason score 2 6 T1c T2a
Prostate Brachytherapy
Advantages over standard EBRT:
Does not require 6 - 7 weeks of daily fractionated treatments Less long-term toxicity due to radiation of adjacent organs Lower incidence of erectile dysfunction Day surgery procedure requiring only a single visit
Cobalt- 60
Definition
Gray: A unit of absorbed radiation equal to the dose of one joule of energy absorbed per kilogram of matter, or 100 rads.
Typical doses
Palliative therapy 8 Gy in 1 fraction 20 Gy in 5 fractions 42.5 Gy in 16 50 Gy in 25 60 Gy in 30 78 Gy in 39
Adjuvant therapy
Radical Doses
Palliative Radiotherapy
Palliative radiotherapy
Relief of symptoms (bone met) Prevention of symptoms or morbidity
Improve survival duration (brain mets)
CT Chest/abdomen, CT Brain, Bone scan demonstrate 14cm lung mass invading into the mediastinum (unresectable) but no mets.
PFTs demonstrate FEV1 0.8L and DLCO 36%
Stage IV : metastatic
Precision mounted
4mm 4cm target Rigid Immobilization
Gamma Knife
Linear Accelerator
Linear Accelerator
X-rays Higher energy (4 - 18Mv)
compared to Gamma rays (1.25 Mv)
Higher energy means More penetrating beam Treat deeper tumors Enhanced skin sparing
Cranial Radiosurgery
Indications Solitary Brain Met on MRI
< 4 cm maximal dimension
Adjuvant Radiotherapy
Definition
Adjuvant Therapy: Post-operative treatment in the absence of demonstrable residual disease, to reduce the possibility of recurrence.
Breast Conservation
No difference in OS LR uncommon post adjuvant XRT LR can be salvaged with further surgery
Breast Tangents
Postmastectomy Radiotherapy
Standard for High Risk disease Tumor > 5cm (T3) Tumor involves skin or chest wall (T4) 4 or more lymph nodes
LRR 25-30% postmastectomy LRR 5- 10% post Locoregional radiotherapy OS improves 5%
Postmastectomy Radiotherapy
Intermediate Risk disease
T2 tumor with multiple adverse features
High grade, LVI+, ER-
1-3 lymph nodes Age < 45 years LRR 10 -18% postmastectomy LRR 5% post Locoregional radiotherapy
3D Conformal Radiotherapy
3D Conformal Radiotherapy
Acquire 3D spacial data Radiation Planning in 3D
Deliver Radiation in 3D
CT Simulator
Couch
contrast allows better differentiation between normal tissues and many tumors Disadvantages:
Treatment Planning
Beam Placement
Prostate Radiotherapy
Prostate 3D Planning
AP View
Lateral View
Increasing Conformality
Advantages
Enhanced Normal Tissue Sparing
Reduces side effects
The Future
Targeting System
X-ray sources
Image detectors
Thank-you!